There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

The study was backed by the Aufzien Family Center for the Prevention and Treatment of Parkinson's Disease at ... Does ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making ... researchers were able to halt the development of dyskinesia symptoms and effectively erase the brain's ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

In addition, they often have milder symptoms, especially in the early stages ... have a different prognosis and do not ...

Among the symptoms, losing one's sense of smell could be an easily missed early indicator. The University of Auckland ...

Israeli scientists have identified a promising new factor in the pathology of Parkinson’s disease that could pave the way for ...

While Parkinson’s disease (PD) has a large and highly generalised therapeutic market, key opinion leaders (KOLs) interviewed ...

Early initiation of pimavanserin among patients with Parkinson disease psychosis were more likely to experience complete symptom resolution.

(Image Credits: Pixabay) Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs). With current ...